By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Idera Pharmaceuticals, Inc. 

167 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592


SEARCH JOBS

Idera Pharma develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit www.iderapharma.com.


Key Statistics


Email: info@iderapharma.com
Ownership: Public

Web Site: Idera Pharma
Employees:
Symbol: IDRA
 









Company News
Idera Pharma (IDRA) Reports First Quarter 2017 Financial Results And Provides Corporate Update 5/5/2017 11:27:15 AM
Idera Pharma (IDRA) Founder and Research Head to Retire 4/19/2017 11:14:40 AM
Idera Pharma (IDRA) Advances Investigational Treatment—Intratumoral IMO-2125 In Combination With Ipilimumab - For Unmet Need In Anti-PD-1 Refractory Metastatic Melanoma 4/11/2017 10:11:11 AM
Analyst Calls For Exponential Upside For Idera Pharma (IDRA) 3/27/2017 5:44:33 AM
Idera Pharma (IDRA) Reports Fourth Quarter And Year End 2016 Financial Results And Provides Corporate Update 3/16/2017 10:33:26 AM
Idera Pharma (IDRA) Presents Update From Ongoing Phase I Dose Escalation Clinical Trial Of Intratumoral IMO-2125 In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment At The 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 2/27/2017 8:22:22 AM
Idera Pharma (IDRA) Announces Appointment Of Jonathan Yingling, Ph.D. As Senior Vice President Of Early Development 2/6/2017 9:46:23 AM
Idera Pharma (IDRA), Vivelix Pharma Forge $155 Million+ Gastrointestinal R&D Pact 11/28/2016 5:40:28 AM
Idera Pharma (IDRA) Reports Translational Data Supporting The Mechanism Of Action Of Intratumoral IMO-2125 From Ongoing Phase I Dose Escalation In Clinical Trial In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment 11/14/2016 8:38:12 AM
Idera Pharma (IDRA) Reports Third Quarter 2016 Financial Results 10/28/2016 7:58:21 AM
12345678910...
//-->